Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it has executed securities purchase agreements to raise gross proceeds of approximately $12.5 million in a private placement financing of common stock and warrants (“Units”). The financing was led primarily by existing institutional shareholders.
$1000 Invested In Nucor 10 Years Ago Would Be Worth This Much Today
Nucor (NYSE:NUE) has outperformed the market over the past 10 years by 1.05% on an annualized basis producing an average annual return of 12.43%. Currently, Nucor has a market capitalization of $34.62 billion.
